VRTX catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 15, 2026Sponsor estimate | NCT07868926Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseVertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD) | VRTXLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT06747572Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseVertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD) | VRTXLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07868926Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseVertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06747572Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseVertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD)Active, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 25, 2027Sponsor estimate | NCT06696443Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Vertex Pharmaceuticals Incorporated · Diabetic Peripheral Neuropathic Pain | VRTXLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 25, 2027Sponsor estimatePhase 3NCT06696443Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Vertex Pharmaceuticals Incorporated · Diabetic Peripheral Neuropathic PainActive, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 2, 2027Sponsor estimate | NCT06185764A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Vertex Pharmaceuticals Incorporated · Myotonic Dystrophy Type 1 (DM1) | VRTXLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 2, 2027Sponsor estimatePhase 1/Phase 2NCT06185764A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Vertex Pharmaceuticals Incorporated · Myotonic Dystrophy Type 1 (DM1)Active, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.